44 results on '"Wells, Philip"'
Search Results
2. Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors
3. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study
4. Circulating Blood Biomarkers and Risk of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis
5. Treatment of venous thromboembolism with rivaroxaban in relation to body weight
6. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism
7. Graduated compression stockings to treat acute leg pain associated with proximal DVT
8. Non-OO blood type influences the risk of recurrent venous thromboembolism
9. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada
10. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode
11. Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10
12. VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of management outcome studies
13. Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism
14. Inter-observer reliability of measures to assess the post-thrombotic syndrome
15. Appropriateness of diagnostic strategies for evaluating suspected venous thromboembolism
16. Factor XIII Val34Leu variant and the risk of myocardial infarction
17. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada – is it necessary to define a new upper reference range for factor VIII?
18. The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism
19. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review
20. Thrombolysis in Deep Vein Thrombosis: Is there still an Indication?
21. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism
22. Treatment of venous thromboembolism with rivaroxaban in relation to body weight
23. Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer
24. Improvements in the Diagnostic Approach for Patients with Suspected Deep Vein Thrombosis or Pulmonary Embolism
25. Application of a Diagnostic Clinical Model for the Management of Hospitalized Patients with Suspected Deep-vein Thrombosis
26. A Paired Comparison of the Accuracy of Two Impedance Plethysmographs
27. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism
28. Application of a Novel and Rapid Whole Blood Assay for D-Dimer in Patients with Clinically Suspected Pulmonary Embolism
29. Comparison of the Accuracy of Impedance Plethysmography and Compression Ultrasonography in Outpatients with Clinically Suspected Deep Vein Thrombosis
30. Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin
31. Graduated compression stockings to treat acute leg pain associated with proximal DVT
32. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism
33. Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10
34. Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism
35. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism
36. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia
37. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada – is it necessary to define a new upper reference range for factor VIII?
38. The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism
39. Thrombolysis in Deep Vein Thrombosis: Is there still an Indication?
40. Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer
41. Improvements in the Diagnostic Approach for Patients with Suspected Deep Vein Thrombosis or Pulmonary Embolism
42. Inter-observer reliability of measures to assess the post-thrombotic syndrome
43. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
44. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.